Palliative care in amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis

Journal of Palliative Medicine

Volumn 10, Issue 2, 2007, Pages 433-457

  Elman, Lauren B ^a   Houghton, David J ^a   Wu, Gregory ^a   Hurtig, Howard I ^a   Markowitz, Clyde E ^a   McCluskey, Leo ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CANNABINOID; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; INFLUENZA VACCINE; LORAZEPAM; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PNEUMOCOCCUS VACCINE; QUINIDINE; QUININE SULFATE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AKINESIA; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BLURRED VISION; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNICATION DISORDER; CONSTIPATION; DEPRESSION; DIET THERAPY; DYSAUTONOMIA; DYSKINESIA; DYSPHAGIA; DYSPNEA; DYSTONIA; FATIGUE; FREEZING; HOSPICE; HUMAN; HYDRATION; HYPERSALIVATION; HYPOKINESIA; INCONTINENCE; LARYNX SPASM; MENTAL DISEASE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NURSING; PALLIATIVE THERAPY; PARKINSON DISEASE; POSITIVE END EXPIRATORY PRESSURE; PSEUDOBULBAR PALSY; RESPIRATORY FAILURE; REVIEW; SENSORY DYSFUNCTION; SLEEP DISORDER; SPASTICITY; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; MULTIPLE SCLEROSIS; PALLIATIVE CARE; PARKINSON DISEASE; QUALITY OF LIFE; TERMINAL CARE;

EID: 34248350692     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.9978     Document Type: Review

References (238)

1. Strong M, Rosenfeld J: Amyotrophic lateral sclerosis: A review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:136-143.
2. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comment]. N Engl J Med 1994;330:585-591.
3. Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V; European ALS Study Group: Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:159-164.
4. De Valck C, Bensing J, Bruynooghe R: Medical students' attitudes towards breaking bad news: An empirical test of the World Health Organization model. Psychooncology 2001;10:398-409.
5. Grassi L, Giraldi T, Messina EG, Magnani K, Valle E, Cartei G: Physicians' attitudes to and problems with truth-telling to cancer patients. Support Care Cancer 2000;8:40-45.
6. Christaki K: A personal reflection on the issues surrounding the use of euphemisms following sudden death [see comment]. Nurs Crit Care 1998;3:249-252.
7. Burton MV, Parker RW: Psychological aspects of cancer surgery: Surgeons' attitudes and opinions. Psychooncology 1997;6:47-64.
8. Buckman R: Breaking bad news: Why is it still so difficult? Br Med J Clin Res Ed 1984;288:1597-1599.
9. Ptacek JT, Ptacek JJ, Ellison NM: "I'm sorry to tell you." Physicians' reports of breaking bad news. J Behav Med 2001;24:205-217.
10. Ellis PM, Tattersall MH: How should doctors communicate the diagnosis of cancer to patients? Ann Med 1999;31:336-341.
11. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC: Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 1997;12:166-173.
12. Southam Y: Improving communication when giving bad news. Nurs Standard 2000;14:57.
13. Angelos P, DaRosa DA, Derossis AM, Kim B: Medical ethics curriculum for surgical residents: Results of a pilot project. Surgery 1999;126:701-705; discussion 705-707.
14. Betson CL, Fielding R, Wong G, Chung SF, Nestel DF: Evaluation of two videotape instruction programmes on how to break bad news - For Cantonese-speaking medical students in Hong Kong. J Audiov Media Med 1997;20:172-177.
15. Campbell EM, Sanson-Fisher RW: Breaking bad news. 3: Encouraging the adoption of best practices. Behav Med 1998;24:73-80.
16. Colletti, L., Gruppen L, Barclay M, Stern D: Teaching students to break bad news. Am J Surg 2001;182:20-23.
17. Davies E, Hopkins A: Good practice in the management of adults with malignant cerebral glioma: Clinical guidelines. Working Group, Royal College of Physicians. Br J Neurosurg 1997;11:318-330.
18. Garg A, Buckman R, Kason Y: Teaching medical students how to break bad news. CMAJ 1997;156:1159-1164.
19. Knox JD, Thomson GM: Breaking bad news: Medical undergraduate communication skills teaching and learning. Med Educ 1989;23:258-261.
20. Rosenbaum ME, Wilson JF, Sloan DA: Clinical instruction for delivering bad news. Acad Med 1996;71:529.
21. Vaidya VU, Greenberg LW, Patel KM, Strauss LH, Pollack MM: Teaching physicians how to break bad news: A 1-day workshop using standardized parents. Arch Pediatr Adolesc Med 1999;153:419-422.
22. Vetto JT, Elder NC, Toffler WL, Fields SA: Teaching medical students to give bad news: does formal instruction help? J Cancer Educ 1999;14:13-17.
23. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP: SPIKES: A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 2000;5:302-311.
24. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA: Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-1323.
25. Doyle D, O'Connell S: Breaking bad news: Starting palliative care. J R Soc Med 1996;89:590-591.
26. Bahr GM, Stanford JL, Costello AM: Bad news from north Lebanon. Tubercle 1991;72:73-74.
27. Post SG, Whitehouse PJ: Fairhill guidelines on ethics of the care of people with Alzheimer's disease: A clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association [see comment]. J Am Geriatr Soc 1995;43:1423-1429.
28. Girgis A, Sanson-Fisher RW: Breaking bad news: Consensus guidelines for medical practitioners. J Clin Oncol 1995;13:2449-2456.
29. Ptacek JT, Eberhardt TL: Breaking bad news. A review of the literature [see comment]. JAMA 1996;276:496-502.
30. Ambuel B, Mazzone MF: Breaking bad news and discussing death. Prim Care 2001;28:249-267.
31. Damian D, Tattersall MH: Letters to patients: Improving communication in cancer care. Lancet 1991;338:923-925.
32. Moss AH: The need for more physician communication with patients/families facing the end of life. W V Med J 2001;97:206-208.
33. Buckman R: How to break bad news: A guide to health care professionals. In: How To Break Bad News. Baltimore: Johns Hopkins University Press, 1992.
34. McCluskey L, Casarett D, Siderowf A: Breaking the news: A survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:131-135.
35. Johnston M, Earll L, Mitchell E, Morrison V, Wright S: Communicating the diagnosis of motor neurone disease. Palliat Med 1996;10:23-34.
36. Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M, Miller RG, Appel SH, Benditt J, Bernat JL, Borasio GD, Carver AC, Clawson L, Del Bene ML, Kasarskis EJ, LeGrand SB, Mandler R, McCarthy J, Munsat T, Newman D, Sufit RL, Versenyi A: Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:145-154.
37. Kaplan LM, Hollander D: Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994;154:675-681.
38. Varrato J, Siderowf A, Damiano P, Gregory S, Feinberg D, McCluskey L: Postural change of forced vital capacity predicts some respiratory symptoms in ALS. Neurology 2001;57:357-359.
39. Elman LB, Siderowf AD, McCluskey LF: Nocturnal oximetry: Utility in the respiratory management of amyotrophic lateral sclerosis. Am J Phys Med Rehab 2003;82:866-870.
40. Fallat RJ, Jewitt B, Bass M, Kamm B, Norris FH Jr.: Spirometry in amyotrophic lateral sclerosis. Arch Neur 1979;36:74-80.
41. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T: Bipap improves survival and rate of pulmonary function decline in patients with ALS [see comment]. J Neurol Sci 1999;164:82-88.
42. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML: Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: Survival rates in a controlled trial. J Neurol Sci 1995;129(suppl):19-26.
43. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H: Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis [see comment]. Ann Intern Med 1997;127:450-453.
44. Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, Leigh PN, Moxham J: A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001;57:153-156.
45. Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ: Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 2003;61:171-177.
46. Murphy PL, Albert SM, Weber CM, Del Bene ML, Rowland LP: Impact of spirituality and religiousness on outcomes in patients with ALS. Neurology 2000;55:1581-1584.
47. Albert SM, Murphy PL, Del Bene ML, Rowland LP: A prospective study of preferences and actual treatment choices in ALS [see comment]. Neurology 1999;53:278-283.
48. Mosenthal AC, Lee KF: Management of dyspnea at the end of life: Relief for patients and surgeons [see comment]. J Am Coll Surg 2002;194:377-386.
49. Voltz R, Borasio GD: Palliative therapy in the terminal stage of neurological disease. J Neurol 1997;244(Suppl 4):S2-10.
50. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, Couratier P: Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001;74:328-334.
51. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P: Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:91-96.
52. Berenstein EG, Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005(2):CD004310.
53. The role of percutaneous endoscopic gastrostomy in enteral feeding. Guidelines for clinical application. Gastrointest Endosc 1988;34(3 Suppl)35S-36S.
54. Jarnagin WR, Duh QY, Mulvihill SJ, Ridge JA, Schrock TR, Way LW: The efficacy and limitations of percutaneous endoscopic gastrostomy. Arch Surg 1992;127:261-264.
55. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM: Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994;40:463-469.
56. Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M: Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695-698.
57. Forbes RB, Colville S, Swingler RJ; Scottish Motor Neurone Disease Research Group: Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease - A record linkage study from the Scottish Motor Neurone Disease Register. J Neurol 2004;251:813-817.
58. Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, Rosenfeld J, Shefner JM, Strong MJ, Sufit R, Anderson FA; ALS CARE Study Group: Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:177-185.
59. Gregory S, Siderowf A, Golaszewski AL, McCluskey L: Gastrostomy insertion in ALS patients with low vital capacity: Respiratory support and survival. Neurology 2002;58:485-487.
60. Boitano LJ, Jordan T, Benditt JO: Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS [see comment]. Neurology 2001;56:413-414.
61. Ondo WG, Hunter C, Moore W: A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40.
62. Mancini, F., Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C: Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003;18:685-688.
63. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV: Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis [see comment]. J Neurol Neurosurg Psychiatry 2000;69:121-123.
64. Pal PK, Calne DB, Calne S, Tsui JK: Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-247.
65. Ellies M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawi R: Reduction of salivary flow with botulinum toxin: Extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope 2004;114:1856-1860.
66. Lipp A., Trottenberg T, Schink T, Kupsch A, Arnold G: A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-1281.
67. Racette BA, Good L, Sagitto S, Perlmutter JS: Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003;18:1059-1061.
68. Halama AR: Surgical treatment of oropharyngeal swallowing disorders. Acta Otorhinolaryngol Belg 1994;48:217-227.
69. Hockstein NG, Samadi DS, Gendron K, Handler SD: Sialorrhea: A management challenge. Am Fam Physician 2004;69:2628-2634.
70. Broniatowski M, Sonies BC, Rubin JS, Bradshaw CR, Spiegel JR, Bastian RW, Kelly JH: Current evaluation and treatment of patients with swallowing disorders. Otolaryngol Head Neck Surg 1999;120:464-473.
71. Borg M. Hirst F: The role of radiation therapy in the management of sialorrhea. Int J Radiat Oncol Biol Physics 1998;41:1113-1119.
72. Castell JA, Stumacher SG, Castell DO: Approach to patients with oropharyngeal dysphagia. Gastroenterologist 1994;2:14-19.
73. Domenech E, Kelly L: Swallowing disorders. Med Clin North Am 1999;83:97-113.
74. Arens R, Gozal D, Omlin KJ, Vega J, Boyd KP, Keens TG, Woo MS: Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150:1154-1157.
75. Pryor JA: Physiotherapy for airway clearance in adults. Eur Respir J 1999;14:1418-1424.
76. Perrin C, Unterborn JN, Ambrosio CD, Hill NS.: Pulmonary complications of chronic neuromuscular diseases and their management [see comment]. Muscle Nerve 2004;29:5-27.
77. Vianello A, Corrado A, Arcaro G, Gallan F, Ori C, Minuzzo M, Bevilacqua M.: Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections. Am J Phys Med Rehabil 2005;84:83-88; discussion 89-91.
78. Winck JC, Goncalves MR, Lourenco C, Viana P, Almeida J, Bach JR: Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest 2004;126:774-780.
79. Sancho J, Servera E, Vergara P, Marin J: Mechanical insufflation- exsufflation vs. tracheal suctioning via tracheostomy tubes for patients with amyotrophic lateral sclerosis: A pilot study. Am J Phys Med Rehabil 2003;82:750-753.
80. Chatwin M, Ross E, Hart N, Nickol AH, Polkey MI, Simonds AK: Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness [see comment]. Eur Respir J 2003;21:502-508.
81. Hanayama K, Ishikawa Y, Bach JR: Amyotrophic lateral sclerosis. Successful treatment of mucous plugging by mechanical insufflation-exsufflation. Am J Phys Med Rehab 1997;76:338-339.
82. Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD: The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001;191:133-137.
83. Ashworth NL, Satkunam LE, Deforge D: Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Syst Rev 2004(1):CD004156.
84. de Carvalho M: Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:47-48.
85. Shakespeare DT, Boggild M, Young C: Anti-spasticity agents for multiple sclerosis [update of Cochrane Database Syst Rev. 2001;(4):CD001332]. Cochrane Database Syst Rev 2003(4):CD001332.
86. Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT: Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95-104.
87. Marquardt G, Seifert V: Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002;72:275-276.
88. Brasic JR: Should people with nocturnal leg cramps drink tonic water and bitter lemon? Psychol Rep 1999;84:355-367.
89. Mandal AK, Abernathy T, Nelluri SN, Stitzel V: Is quinine effective and safe in leg cramps? J Clin Pharmacol 1995;35:588-593.
90. Hecht M, Hillemacher T, Grasel E, Tigges S, Winterholler M, Heuss D, Hilz MJ, Neundorfer B: Subjective experience and coping in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:225-231.
91. Kubler A, Mellinger J, Vaughan TM, Pawelzik H, Schalk G, McFarland DJ, Birbaumer N, Wolpaw JR: Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface. Neurology 2005;64:1775-1777.
92. Gallagher JP: Pathologic laughter and crying in ALS: A search for their origin. Acta Neurol Scand 1989;80:114-117.
93. Schiffer RB, Herndon RM, Rudick RA: Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985;312:1480-1482.
94. Iannaccone S, Ferini-Strambi L: Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996;19:532-535.
95. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA; AVP-923 ALS Study Group: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial [see comment]. Neurology 2004;63:1364-1370.
96. Kilani M, Micallef J, Soubrouillard C, Rey-Lardiller D, Demattei C, Dib M, Philippot P, Ceccaldi M, Pouget J, Blin O: A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:46-54.
97. Rabkin JG, Albert SM, Del Bene ML, O'Sullivan I, Tider T, Rowland LP, Mitsumoto H: Prevalence of depressive disorders and change over time in late-stage ALS [see comment]. Neurology 2005;65:62-67.
98. Lou JS, Reeves A, Benice T, Sexton G : Fatigue and depression are associated with poor quality of life in ALS [see comment]. Neurology 2003;60:122-123.
99. Ganzini L, Johnston WS, Hoffman WF: Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999;52:1434-1440.
100. Ganzini L, Johnston WS, Silveira MJ: The final month of life in patients with ALS. Neurology 2002;59:428-431.
101. World Health Organization: Cancer pain relief. Report of the WHO Expert Committee. Technical Reprt Series 1990, p. 840.
102. Delbene M. Forced vital capacity: Implications for hospice care. International Alliance of Motor Neuron Disease (poster presentation), 1998.
103. McCluskey L, Houseman G: Medicare hospice referral criteria for patients with amyotrophic lateral sclerosis: A need for improvement. J Palliat Med 2004;7:47-53.
104. von Gunten C, Weissman DE: Ventilator withdrawal protocol. J Palliat Med 2003;6:773-774.
105. von Gunten C, Weissman DE: Symptom control for ventilator withdrawal in the dying patient. J Palliat Med 2003;6:774-775.
106. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response [see comment]. Arch Neurol 2002;59:102-112.
107. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F: Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
108. Widnell KL, Comella C: Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 2005;20(Suppl 11):S30-37.
109. Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I; F-01 Study Group: Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open, multicenter study. Eur Neurol 2001;45:111-118.
110. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
111. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 2001;56(11 Suppl 5):S1-88.
112. Micieli G Tosi P, Marcheselli S, Cavallini A: Autonomic dysfunction in Parkinson's disease [see comment]. Neurol Sci 2003;24(Suppl 1):S32-34.
113. McMahon MM, Hurley DL, Kamath PS, Mueller PS: Medical and ethical aspects of long-term enteral tube feeding [see comment]. Mayo Clin Proc 2005;80:1461-1476.
114. Khokhar N, Gill ML: Percutaneous endoscopic gastrostomy: Nine years experience in a tertiary care centre in Pakistan. J Pak Med Assoc 2005;55:108-110.
115. Luman W, Kwek KR, Loi KL, Chiam MA, Cheung WK, Ng HS: Percutaneous endoscopic gastrostomy - Indications and outcome of our experience at the Singapore General Hospital. Singapore Med J 2001;42:460-465.
116. Grosset KA, Grosset DG: Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord 2005;20:616-619.
117. Waters C: Other pharmacological treatments for motor complications and dyskinesias. Mov Disord 2005;20(Suppl 11):S38-44.
118. Jankovic J, Tintner R: Dystonia and parkinsonism. Parkinsonism Relat Disord 2001;8:109-121.
119. Karstaedt PJ, Pincus JK: Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992;49:149-151.
120. Pincus JH, Barry K: Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987;44:270-272.
121. Manson AJ, Turner K, Lees AJ: Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
122. Stacy M: Apomorphine: North American clinical experience. Neurology 2004;62(6 Suppl 4):S18-21.
123. Rascol O: Transdermal delivery of dopaminergic agents. Neurology 2005;65(2 Suppl 1):S1-2.
124. Nilsson D, Nyholm D, Aquilonius SM: Duodenal levodopa infusion in Parkinson's disease - Long-term experience. Acta Neurol Scand 2001;104:343-348.
125. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H: Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease [see comment]. Neurology 2005;64:216-223.
126. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
127. Schrag A: Psychiatric aspects of Parkinson's disease - An update. J Neurol 2004;251:795-804.
128. Holroyd S, Currie L, Wooten GF: Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
129. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
130. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis [erratum appears in Clin Neuropharmacol 2004;27:256]. Clin Neuropharmacol 2004;27:153-156.
131. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM: Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300.
132. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R; Parkinson Study Group: Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
133. Food and Drug Administration: FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. 2005.
134. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA: Risk of death in elderly users of conventional vs. atypical antipsychotic medications [see comment]. N Engl J Med 2005;353:2335-2341.
135. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S: Depression in Parkinson's disease: Clinical correlates and outcome. Parkinsonism Relat Disord 2003;10:23-28.
136. Weintraub DSM: Psychiatric complications of Parkinson's disease. Am J Geriatr Psychiatry 2005;13:844-851.
137. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
138. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG: A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377-382.
139. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease [see comment]? J Neurol Neurosurg Psychiatry 2000;69:308-312.
140. Aarsland DPR, Brown A, Larsen JP, Ballard C: Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Ann Neurol 2005;58:773-776.
141. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM: Prognosis of Parkinson disease: Risk of dementia and mortality: The Rotterdam Study. Arch Neurol 2005;62:1265-1269.
142. Burn DJ, McKeith IG: Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003;18(Suppl 6):S72-79.
143. Aarsland D, Mosimann UP, McKeith IG: Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-171.
144. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study [erratum appears in J Neurol Neurosurg Psychiatry 2002;73:354]. J Neurol Neurosurg Psychiatry 2002;72:708-712.
145. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19:1-8.
146. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T: Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study [see comment]. J Neurol Neurosurg Psychiatry 2005;76:934-939.
147. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease [see comment]. N Engl J Med 2004;351:2509-2518.
148. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study [see comment]. Lancet 2000;356:2031-2036.
149. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology: Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
150. Adler CH: Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-29.
151. Zoldan J, Friedberg G, Livneh M, Melamed E: Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist [see comment]. Neurology 1995;45:1305-1308.
152. Proulx M, de Courval FP, Wiseman MA, Panisset M: Salivary production in Parkinson's disease. Mov Disord 2005;20:204-207.
153. Wenning GK, Geser F, Poewe W: Therapeutic strategies in multiple system atrophy. Mov Disord 2005; 20(Suppl 12):S67-76.
154. Schenck CH: A polysomnagraphic neurologic, psychiatric and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): Sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleve Clin J Med 1990;57(suppl):10-24.
155. Adler CH, Thorpy MJ: Sleep issues in Parkinson's disease. Neurology 2005;64(12 Suppl 3):S12-20.
156. Boeve BF, Silber MH, Ferman TJ: Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
157. Takeuchi N, Uchimura N, Hashizume Y, Mukai M, Etoh Y, Yamamoto K, Kotorii T, Ohshima H, Ohshima M, Maeda H: Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001;55:267-269.
158. Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, Rye B; Medical Advisory Board of the Restless Legs Syndrome Foundation An algorithm for the management of restless legs syndrome [erratum appears in Mayo Clin Proc 2004;79:1341]. Mayo Clin Proc 2004;79:916-922.
159. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A, Gruber G, Hauer C, Saletu B: Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): Acute placebo-controlled sleep laboratory studies with clonazepam. European Neuropsychopharmacology 2001;11:153-161.
160. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G: Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study [see comment]. Neurology 2002;59:1573-1579.
161. Stiasny KW, Trenkwalder TC, Oertel WH: Restless legs syndrome and its treatment by dopamine agonists. Parkinsonism Relat Disord 2000;7:21-25.
162. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S: Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004; 251:579-583.
163. Chudler EH, Dong WK: The role of the basal ganglia in nociception and pain. Pain 1995;60:3-38.
164. Azher SN, Jankovic J: Camptocormia: Pathogenesis, classification, and response to therapy. Neurology 2005;65:355-359.
165. Waseem S, Gwinn-Hardy K: Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001;110:33-34.
166. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group: Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64:87-93.
167. Gorell JM, Johnson CC, Rybicki BA: Parkinson's disease and its comorbid disorders: An analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-1868.
168. Morrison RS, Siu AL: Survival in end-stage dementia following acute illness [see comment]. JAMA 2000;284:47-52.
169. Calne, Late-stage Parkinson's disease for the rehabilitation specialist: A nursing persepective. Topics Geriatr Rehab 2005;21:233-246.
170. Hudson PT, Kristjanson LJ: Would people with Parkinson's disease benefit from palliative care? Palliat Med 2006;20:87-94.
171. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M: Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 2006;12:35-41.
172. Martinez-Martin P, Benito-Leon J, Alonso F, Catalan MJ, Pondal M, Zamarbide I: Health-related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ-8 and EuroQoL-5D. Mov Disord 2004;19:312-318.
173. Rees J, O'Boyle C, MacDonagh R: Quality of life: impact of chronic illness on the partner [see comment]. J R Soc Med 2001;94:563-566.
174. MacMahon DG, Thomas S: Practical approach to quality of life in Parkinson's disease: The nurse's role. J Neurol 1998;245(Suppl 1):S19-22.
175. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis [see comment]. N Engl J Med 2000;343:938-952.
176. Hauser SG, Goodin DS: Multiple sclerosis and other demyelinating diseases. In: Braunwalk E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds): Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2005, pp. 2461-2471.
177. Whetten-Goldstein, K., Sloan FA, Goldstein LB, Kulas ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425.
178. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK: Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005;62:1345-1356.
179. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH: A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999;5:369-376.
180. Kantarci OH, Weinshenker BG: Natural history of multiple sclerosis. Neurol Clin 2005;23:17-38.
181. Lublin FD: Clinical features and diagnosis of multiple sclerosis. Neurol Clin 2005;23:1-15.
182. Ben-Zacharia AB, Lublin FD: Palliative care in patients with multiple sclerosis. Neurol Clin 2001;19:801-827.
183. Milanov I: Clinical and neurophysiological correlations of spasticity. Funct Neurol 1999;14:193-201.
184. Katz RT: Management of spasticity. Am J Phys Med Rehab 1988;67:108-116.
185. Beard S, Hunn A, Wight J: Treatments for spasticity and pain in multiple sclerosis: A systematic review. Health Technol Assess 2003;7:iii.
186. Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J, Gardner BP, Teddy P, Jamous A, Weinmann P: Intrathecal baclofen for long-term treatment of spasticity: A multi-centre study [see comment]. J Neurol Neurosurg Psychiatry 1989;52:933-939.
187. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T, Terpstra S, Stewart R: Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-209.
188. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C: Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study [see comment]. J Neurol Neurosurg Psychiatry 2000;68:707-712.
189. Bittencourt PR: Oxcarbazepine and spasticity: Further observations. Arq Neuropsiquiatr 1988;46:382-384.
190. Morgan JC, Hess DC, Sethi KD: Botulinum toxin treatment of painful tonic spasms in multiple sclerosis [see comment]. Neurology 2004;62:2143; author reply 2143.
191. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, Murray TJ: Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994;58:89-93.
192. Moulin DE: Pain in central and peripheral demyelinating disorders. Neurol Clin 1998;16:889-898.
193. Brown RF, Tennant CC, Dunn SM, Pollard JD: A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables. Mult Scler 2005;11:477-484.
194. Al-Smadi J, Warke K, Wilson I, Cramp AF, Noble G, Walsh DM, Lowe-Strong AS: A pilot investigation of the hypoalgesic effects of transcutaneous electrical nerve stimulation upon low back pain in people with multiple sclerosis. Clin Rehab 2003;17:742-749.
195. Samkoff LM, Daras M, Tuchman AJ, Koppel BS: Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology 1997;49:304-305.
196. Houtchens MK, Richert JR, Sami A, Rose JW: Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997;3:250-253.
197. Finnerup NB, Gottrup H, Jensen TS: Anticonvulsants in central pain. Expert Opin Pharmacoth 2002;3:1411-1420.
198. Schneker BF: Pregabalin: A new neuromodulator with broad therapeutic indications. Ann Pharmacother 2002;39:2029-2037.
199. Malfitano AM, Bifulco MG: From cannabis to endocannabinoids in multiple sclerosis: A paradigm of central nervous system autoimmune diseases. Curr Drug Targets CNS Neurol Disord 2005;4:667-675.
200. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial [see comment]. Lancet 2003;369:1517-1526.
201. Wingerchuk D: Cannabis for medical purposes: cultivating science, weeding out the fiction [see comment]. Lancet 2004;364:315-316.
202. Auger CM, Duquette P: Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology 2005;65:1652-1653.
203. Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL: Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6:141-147.
204. McDonald WI, Barnes D: The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry 1992;55:747-752.
205. Blake DJ, Bodine C: An overview of assistive technology for persons with multiple sclerosis. J Rehab Res Dev 2002;39:299-312.
206. Selhorst JB, Saul RF; Uhthoff and his symptom [comment; erratum appears in J Neuroophthalmol 1995;15:264]. J Neuroophthalmol 1995;15:63-69.
207. Robinson LR, Kraft GH, Fitts SS, Schneider V: Body cooling may not improve somatosensory pathway function in multiple sclerosis. Am J Phys Med Rehab 1997;76:191-196.
208. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Finazzi Agro E, Collura G, Vespasiani G: Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehab 1999;80:437-441.
209. Gaines KK: Phenazopyridine hydrochloride: the use and abuse of an old standby for UTI. Urol Nurs 2004;24:207-209.
210. Hawker KF: Bladder, bowel, and sexual dysfunction in multiple sclerosis. Curr Treat Options Neurol 2001;3:207-214.
211. Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J: Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehab 1997;11:211-219.
212. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D; Overactive Bladder: Judging Effective Control and Treatment Study Group: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study [see comment]. Mayo Clin Proc 2001;76:358-363.
213. Klaphajone J, Kitisomprayoonkul W, Sriplakit S: Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehab 2005;86:2114-218.
214. Gudziak MR, Tiguert R, Puri K, Gheiler EL, Triest JA: Management of neurogenic bladder dysfunction with incontinent ileovesicostomy. Urology 1999;54:1008-1011.
215. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ: The impact of fatigue on patients with multiple sclerosis [see comment]. Can J Neurol Sci 1994;21:9-14.
216. rd, Kinkel RP: Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-893.
217. Mathiowetz V, Matuska KM, Murphy ME: Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehab 2001;82:449-456.
218. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R: Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo [see comment]. Neurology 1995;45:1956-1961.
219. Stankoff BW, Confavreux C. Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M; French Modafinil Study Group: Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology 2005;64:1139-1143.
220. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study [see comment]. J Neurol Neurosurg Psychiatry 2002;72:179-183.
221. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM: Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002;249:983-987.
222. Wingerchuk DB, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M: A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005;64:1267-1269.
223. Bagert B, Camplair P, Bourdette D; Cognitive dysfunction in multiple sclerosis: Natural history, pathophysiology and management. CNS Drugs 2002;16:445-455.
224. Morgen KS, Courtney SM, Wolters T, Melchoir H, Blecker CR, Oschmann P, Kaps M, Vaitl D: Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006;30:891-898.
225. Amato MP, Zipoli V: Clinical management of cognitive impairment in multiple sclerosis: A review of current evidence. Intl MS J 2003;10:72-83.
226. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE Donepezil improved memory in multiple sclerosis in a randomized clinical trial [see comment]. Neurology 2004;63:1579-1585.
227. Siegert RJ, Abernethy DA: Depression in multiple sclerosis: A review. J Neurol Neurosurg Psychiatry 2005;76:469-475.
228. Janardhan V, Bakshi R: Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. J Neurol Sci 2002;205:51-58.
229. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L: Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942-949.
230. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F: The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175-181.
231. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA: Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 2004;10:679-685.
232. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study.[see comment]. Neurology 2004;63:1788-1795.
233. Pirko I, Rodriguez M: Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: Need for a controlled trial. Arch Neurol 2004;61:1148-1149.
234. Martinelli Boneschi F, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005(4):CD002127.
235. Cohen BA, Mikol DD: Mitoxantrone treatment of multiple sclerosis: Safety considerations. Neurology 2004;63(12 Suppl 6):S28-32.
236. Calcagno P, Ruoppolo G, Grasso MG, De Vincentiis M, Paolucci S: Dysphagia in multiple sclerosis - Prevalence and prognostic factors. Acta Neurol Scand 2002;105:40-43.
237. Pittock SJ, Weinshenker BG, Wijdicks EF: Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:1331-1333.
238. Buchanan RJ, Wang S, Huang C, Graber D: Profiles of nursing home residents with multiple sclerosis using the minimum data set. Mult Scler 2001;7:189-200.